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examined the news reports from online journals, websites, and reputable news 
outlets to determine the most likely reason for drug failure. RESULTS: Of 31 
products included in the analysis 16 failed to meet the expectations announced 
in the month prior to launch. We attributed price or reimbursement as the 
reason that seven of the 16 products failed to meet market expectations. 
Competition due to existing product dominance, near-simultaneous launches for 
the same patient population, and widely available generics explained the failure 
of five products. Efficacy questions and label restrictions contributed to the slow 
uptake of three products. Capacity can be faulted on another product. 
CONCLUSIONS: As the landscape changes, manufacturers must consider 
product differentiation and market assessment early to anticipate the market’s 
price threshold to avoid a key pitfall in new product launches.  
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OBJECTIVES: While many small biotechs are acquired by larger pharmaceuticals, 
few attempt a full scale commercialization of their product. We analyzed the 
stock market returns of three small, single drug bio-technology firms which had 
drugs approved by the FDA in 2010. METHODS: The historical prices adjusted for 
corporate action were used for all three firms from Q4 2007 through Q3 2012 
which accounted for 1,261 trading days per company. All products have been 
approved by the FDA for at least 8 quarters. Each company’s prices were broken 
up into daily and quarterly intervals as well as pre-launch and post-launch. 
Simple statistics and t-tests were run on the stock returns for all intervals. 
RESULTS: On average, the pooled total return associated with the pre-launch 
phase was 212.6% higher than post-launch. The average pooled quarterly and 
daily returns during the pre-launch period were 19.1% and .37% higher than the 
post-launch period, respectively. The standard deviation of the daily returns 
during the pre-launch period was on average 24% higher than during the post-
launch period. A two-tail t-test assuming unequal variances was run on each of 
the daily stock prices with a hypothesized mean difference of 0 between pre-
launch and post-launch, for all three of the companies the p-value was <0.05. 
CONCLUSIONS: Investors seemed to prefer the pre-launch period which received 
a greater return on investment. The difference in the mean prices for each 
company in the different phases was statistically significant. However this 
analysis is relatively early in the post-launch term for each drug as smaller 
companies tend to gain market share more slowly than larger pharmaceuticals. 
The stock returns of these companies seem to be highest in the pre-launch 
phase as opposed to post-launch.  
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OBJECTIVES: To describe the trends in published comparative cost analyses from 
2010 through 2012 for interventions in cancer (CA), diabetes (DM), and 
cardiovascular diseases (CVD). METHODS: A PubMed search of articles published 
between January 2010 and December 2012 was conducted utilizing the following 
search strategy/terms: (cost-effectiveness OR cost-utility OR cost-benefit) AND 
(cancer OR diabetes OR cardiovascular diseases). Articles were excluded if they: 
1) did not contain sufficient information to determine the type of analysis 
conducted; 2) focused on a sequelae of a treatment; 3) no comparative analysis 
was conducted; 4) only costs were considered; or 5) were reviews, editorials, or 
commentaries. The abstracts of the articles, not the full articles themselves, 
were evaluated and used to classify comparative economic analyses by disease 
focus, intervention type, intervention target (e.g., treatment, prevention), 
economic analysis performed, geographic region of population/perspective of the 
analysis, and primary/corresponding author affiliations. Descriptive statistics 
were conducted in PASW Statistics 18.0. RESULTS: The initial search yielded 
3,868 abstracts. Of these, 725 studies were retained in the final analysis (254 in 
2010, 226 in 2011, 245 in 2012). In 2010, 2011 and 2012, respectively, 134, 119, 150 
studies were in CA, 25, 23, 35 in DM, and 95, 84, 60 in CVD. Approximately 63.7% 
of studies across years focused on active treatment or secondary prevention. A 
pharmaceutical, vaccine, or lifestyle intervention was the focus in 47.9% of 
studies. A majority (70.2%) of the studies utilized cost-utility analyses, which was 
consistent across all years, with most study populations/study perspective in 
European countries. CONCLUSIONS: Comparative economic analyses from 2010-
2012 had a heavy focus on active or secondary interventions in CA and in 
European populations. As value-based pricing and health care reform emerges, 
more extensive utilization and publication of comparative cost effectiveness 
analyses will be required.  
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OBJECTIVES: The Health and Economics Bulletin is an electronic periodic of The 
Brazilian Health Surveillance Agency (ANVISA). It aims to provide information to 
health care decision-makers and patients when there is more than one 
pharmaceutical option to treat the same disease and there is no scientific 
evidence of superiority in terms of safety and efficacy among drugs. This bulletin 
intends to improve health care efficiency when it points out the differences on 
treatment costs among the drugs. The objective of this study is to analyze all 
editions of The Health and Economics Bulletin available on ANVISA website. 
METHODS: Data were collected from editions of Health and Economics Bulletin 
published since August 2009 (month of launch) until September 2012. The 
variables considered were: number and type of diseases, therapeutic classes, 
active substance, drugs and treatment costs. RESULTS: Eight editions of the 
bulletin were published and each number addressed a different disease such as 
osteoporosis, glaucoma, gastroesophageal reflux, arterial hypertension, epilepsy, 
dyslipidemia, erectile dysfunction and allergic rhinitis. In total, 12 therapeutic 
classes were evaluated which comprises biphosphonates and oral 
antihistamines on osteoporoses and allergic rhinitis editions, respectively. A 
total of 33 active substances and 64 drugs were assessed, including generics, 
similars and brand drugs. Sixty four costs of treatment were performed which 
demonstrated considerable differences between drugs prescribed for the same 
disease. For example, on the allergic rhinitis edition, it was found 231% of 
difference on treatment costs between the most expensive and the lowest cost 
drugs although they have similar safety and efficacy levels, based on scientific 
evidences. CONCLUSIONS: The Health and Economics Bulletin is an important 
information tool and was elaborated to improve the critical view of health care 
decision-makers and patients. Considering differences of treatment costs among 
drugs that have the same safety and efficacy, they can select the drugs more 
efficiently.  
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OBJECTIVES: The amount of time spent in different activities by inpatient order 
entry pharmacists in a computerized provider order entry (CPOE) versus a non-
CPOE setting. METHODS: A prospective, pretest-posttest, time and motion study 
design was used to compare the workflow of order entry pharmacists in an 
inpatient hospital setting. Randomized data collection was conducted at two 
time periods in the same hospital: the pretest period was immediately before 
implementation of the CPOE system and the posttest period was 5.5 months 
post-implementation. A pre-validated data recording instrument was used to 
record 37 different pharmacist tasks, which were grouped into four activities: 
clinical, distributive, administrative, and miscellaneous. Comparisons of the 
amount of time spent by the order entry pharmacist per hour in each of the four 
different activities were conducted. SAS® version 9.3 was used to analyze the 
data, with statistical significance set at 0.05. RESULTS: A total of 37 hours were 
collected pre-intervention, and 42 hours post-intervention. The amount of time 
(mean number of minutes per hour±SD pre-intervention versus post-
intervention, p-value) for the activities were: clinical (2.0±3.8 vs. 1.9±2.6, p=0.89); 
distributive (45.2±11.3 vs. 49.3±8.1, p=0.11); administrative (10.6±9.8 vs. 6.0±6.5, 
p<0.05); and miscellaneous (2.1±3.2 vs. 2.8± 4.0, p=0.64). CONCLUSIONS: Less time 
was spent by order entry pharmacists in the administrative activity after the 
implementation of CPOE, which translates to more pharmacist time spent in 
other activities. Management should to be aware of the implications of CPOE 
implementation on pharmacist workflow.  
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OBJECTIVES: When developing technology appraisals guidance, NICE (National 
Institute for Health and Clinical Excellence) commissions an independent 
academic centre to critically appraise the manufacturer's submission and 
prepare an Evidence Review Group (ERG) report that reviews the published 
evidence on the relevant technology. NICE has used 11 different academic 
centres to support the work of appraisal committees in the Single Technology 
Appraisal (STA) process and this research aimed to explore whether there were 
differences in acceptance rates between these centres. METHODS: All final 
appraisal determinations (FADs) resulting from STA processes were identified 
(August 2006 – December 2012) from which the recommendation and the 
appraising academic centre were extracted. Acceptance rates were compared 
across the 8 academic centres that made at least 5 recommendations using a Chi 
squared test. RESULTS: This research considered 94 submissions, from which 
106 recommendations were generated. The number of acceptances or rejections 
was not found to differ significantly by centre (p=0.810). Of these centres, the 
highest proportion of NICE positive recommendations followed ERG appraisals 
by Southampton (86%) and the lowest proportion by Liverpool (61%). In between 
were Peninsula (78%), York (77%), Sheffield (76%), Aberdeen (67%), Kleijnen (67%), 
and Birmingham (62%). Nevertheless, the considered therapy areas substantially 
varied between different academic centres, with certain therapy areas being 
preferentially or even exclusively appraised by specific centres. Oncology was 
the most commonly-appraised area overall (47% of recommendations) and the 
appraisal of oncology submissions was not evenly distributed between the 
different academic centres (P<0.001). There were no significant variations in the 
distribution of orphan drugs assessed or in the proportion of restricted 
recommendations issued. CONCLUSIONS: Despite large variations in therapy 
areas considered, the likelihood of a positive recommendation does not appear 
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to vary by the academic centre appraising the submission, reflecting the 
inherent objectivity and uniform implementation of NICE methodology.  
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OBJECTIVES: Chronic disease is resource intensive for health care systems. 
Considerable efforts have focused on the management of chronic disease in the 
community setting however the role of individual health technologies is often 
overlooked. The purpose of this analysis was to identify examples of individual 
health technologies that contribute to overall chronic disease management. 
METHODS: The Medical Advisory Secretariat (MAS) in Ontario has published a 
substantive body of evidence-based analyses on health technologies. The MAS 
Ontario Health Technology Assessment Series was searched for reports 
published between 2006 and 2011. Findings were limited to analyses that 
reported on health technologies with moderate to high quality evidence of 
effectiveness for chronic disease management. Outcomes of interest included 
health resource utilization, patient and clinical outcomes, and economic 
analyses measures. RESULTS: Two technologies had direct evidence of the cure 
of chronic disease. Bariatric surgery was effective in the resolution of diabetes 
among morbidly obese adults (77% resolution; 95% CI 71%-83%), with a cost of 
$15,697 Canadian dollars (CAD) per quality-adjusted life year (QALY) relative to 
usual care. Ablation for atrial fibrillation resulted in greater freedom from 
arrhythmia than medical treatment alone (RR 0.30; 95% CI 0.11-0.79), and 
downstream cost savings. Two technologies were effective in the prevention of 
chronic wounds and 8 technologies were effective in the management of chronic 
obstructive pulmonary disease, stroke, coronary artery disease, congestive heart 
failure or benign prostatic hyperplasia. Among these 10 technologies, all 5 
analyses that reported incremental cost-effectiveness ratios were cost-effective 
based on a $50,000 (CAD) per QALY threshold. CONCLUSIONS: This review 
demonstrates that individual health technologies can be both effective and  
cost-effective in the overall management of chronic disease. Therefore  
health technologies can be a viable contributing factor to chronic disease 
management and should be considered as an integral component of community 
health care.  
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OBJECTIVES: To compare the German (AMNOG) and French (ASMR) category 
scoring pricing systems; and to evaluate whether the two agencies have a similar 
interpretation of innovation and clinical benefit of the same drugs. Our results 
then allow us to theorize the future of European scoring systems. METHODS: A 
search of the G-BA website was conducted to identify all drug-related Health 
Technology Assessments (HTA) published between January 2011 and December 
2012. Once a list of assessments was compiled, we searched the HAS website to 
identify the same drug HTAs published within the same time period. Then, for 
both agencies we identified and compared the methods in which they scored 
both innovation and clinical benefits of these drugs. To note: Germany (G-BA) 
provide AMNOG scorings from 1 (substantial benefit) to 6 (negative additional 
benefit), whilst France (HAS) provide ASMR scorings from I (major improvement) 
to V (no improvement). RESULTS: In this time period, sixteen HTAs were 
published by the G-BA, corresponding to 12 HTAs published by HAS. Upon 
observation of the scoring comparisons, only 3 of the 12 drugs were given the 
same scores by both agencies: Fampridine (AMNOG 5; ASMR V); Cabazitaxel 
(AMNOG 3; ASMR III); Linagliptin (AMNOG 5; ASMR V). For the remaining 12 
drugs, there appeared to be little alignment in the scorings of innovation and 
clinical benefits: Vemurafenib (AMNOG 2; ASMR III), Vandetanib (5; IV), 
Belatacept (3; V), Apixaban (3; IV), Eribulin (6; IV), Collagenase clostridium 
histolyticum (5; no score), Abiraterone acetate (5; III), Fingolimod (3; IV) and 
Ticagrelor (2 and 5; IV). CONCLUSIONS: There does not seem to be a strong 
relationship between the criteria scoring of AMNOG and ASMR, demonstrating 
the heterogeneity of the European market. Whether increased HTA co-operation 
will align scoring more closely, or increased Value Based Pricing structures will 
drive divergence, is yet to be seen.  
 
PHP120  
AN INVESTIGATION INTO THE KEY DRIVERS INFLUENCING THE DECISION 
MAKING OF THE SCOTTISH MEDICINES CONSORTIUM  
Mshelia I1, White R2, Mukku SR2 
1Access Partnership, London, UK, 2The Access Partnership, London, UK  
OBJECTIVES: The main aim of this study was to identify significant implicit and 
explicit factors which play a role in decision making of the Scottish Medicines 
Consortium (SMC). Once these factors have been identified, the degree to which 
they influence the final decision will be ascertained. METHODS: A retrospective 
sample of submissions was taken from the SMC website. A bivariate statistical 
analysis was performed on the data extracted, allowing identification of the 
most fundamental drivers of an SMC decision. RESULTS: Between January 2006 
and September 2011, 577 appraisals were made by the SMC. Of these appraisals, 
27% accepted for full use, 30% were accepted for restricted use, whilst 43% of 
submissions were not recommended for use in Scotland. During this time period, 
the mean ICER for drugs accepted for use is £30,013 and for those that were not 
recommended for use the value was £38,132. Analysis of over 500 submissions to 
the SMC showed that a number of explicit, key drivers in line with SMC criteria 
were significant, including; the unofficial £30,000 ICER limit, the use of 
appropriate economic and clinical comparators, as well as robust demonstration 
of the economic case. Other key drivers which are more implicit, yet critical to 
decision making, were also shown to be significant. These included; the orphan 
status, submissions targeting paediatric populations and restrictions on the 
therapeutic scope of submissions placed by manufacturers. CONCLUSIONS: 
From a manufacturer point of view understanding the tendencies of the SMC is 
critical, as a firmer understanding of the key determinants of the SMC decision 
may lead to improved quality and robustness of future submissions. From the 
perspective of the SMC and the wider society, these insights will allow the public 
and the SMC to review the drivers of the decisions to establish whether they are 
in line with official criteria.  
 
PHP122  
EXCITE – A NEW COLLABORATIVE MODEL OF PRE-MARKET EVALUATION OF 
HEALTH TECHNOLOGIES  
Levin L1, Krahn M2, Goeree R3, Mamdani M4, Easty T5, Fergussoon D6, Moher D7,  
Levine M8, Greve Youg K1, Albert M1, Treurnicht I9, Soloniko J10, Srinivasan V11,  
Lewis B12, Mantel B13, Wright DCW14, Ivey R15 
1MaRS, Toronto, ON, Canada, 2Toronto Health Economics and Technology Assessment (THETA) 
Collaborative, Toronto, ON, Canada, 3PATH Research Institute, McMaster University, Hamilton, 
ON, Canada, 4Li Ka Shing Research Institute, Toronto, ON, Canada, 5University of Toronto, 
Toronto, ON, Canada, 6University of Ottawa end Ottawa Hospital Research Institutute, Ottawa, 
ON, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8Henderson Research Centre, 
Hamilton, ON, Canada, 9MaRS Discovery District, Toronto, ON, Canada, 10Health Technology 
Exchange, Toronto, ON, Canada, 11Ontario Ministry of Health and Long term care, Toronto, ON, 
Canada, 12MEDEC, Totonto, ON, Canada, 13Research, Commercializationand Entrepeneurship 
Division, Toronto, ON, Canada, 14in medical and academic affairs, program planning and 
evaluation, Toronto, ON, Canada, 15MaRS EXCITE, Toronto, ON, Canada  
OBJECTIVES: Many non-drug technologies with regulatory approval fail to be 
recommended for reimbursement. Reasons include low quality evidence or lack 
of relevance Excellence in Clinical Innovation and Technology Evaluation 
(EXCITE) is a collaboration between industry, government and academia to 
develop a harmonized pre-market evaluation that mitigates risk, improves 
adoption, and responds to system needs METHODS: EXCITE works with industry 
to evaluate evidence of efficacy and safety, cost effectiveness and adoption 
realities. It builds on Ontario’s field evaluation experience. Structure: 1) 
Management board representing industry, government, academia and the 
Ontario Health Technology Advisory Committee (OHTAC); 2) Scientific 
collaboration of 7 Methodological Centres (MC) and 24 Academic Health Science 
Centres and a Quality Assurance Committee; and 3) Chief Scientific Officer and 
secretariat. Process: The management board prioritizes applications based on 
innovation, relevance, and commercialization. MCs develop a protocol and 
budget for clinical evaluation, systematic review, and an economic analysis. 
Human factors and usability analysis, and preference studies are offered. 
Consideration is underway for conditions of early adoption. Studies are funded 
by industry through MaRS, which fosters and commercializes innovation. 
RESULTS: Of 17 applications (year 1), 3 have commenced evaluation, 3 are in 
protocol development, discussions ongoing in 3 and one declined. Studies are 
designed to satisfy regulatory and reimbursement requirements and reflect 
complexities of adoption while maintaining high academic standards. Lessons 
learnt include a better understanding of the complexities of adoption and the 
benefit of endorsement in mitigating risk; limited funding for evaluations; 
tension between needs of industry and independence and objectivity of MCs; 
and intricacies of contract structures. CONCLUSIONS: EXCITE is a potential 
alternative to post-market HTA in Ontario, and may improve adoption in other 
jurisdictions. Expansion to a national and international scale will provide global 
reach for evaluated technologies. This is a potentially innovative and powerful 
model of early HTA.  
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OBJECTIVES: Cost effectiveness analyses play a critical role in determining 
coverage of novel drugs and devices. Increasingly, payers are demanding 
subgroup analyses to determine indications which would be covered by  
the national health system or insurance agency. METHODS: To understand  
and review trends in the use of subgroup cost effectiveness analysis, we 
analyzed NICE HTAs for products approved between 2011-2012. Manufacturer 
submissions for CEA were compared to final review and decision by HTA agency. 
Analogs were identified and case studies were developed to further understand 
the use of subgroup analyses and cost effectiveness models. RESULTS: Decisions 
made by NICE in 2011-2012 show increasing trends towards the use of subgroup 
analysis for determining indications for coverage by national payer bodies. 
Between 2011-2012, 80% of the assessments included subgroup analyses. 
Approximately half of them included cost effectiveness analyses for various 
subgroups. Interestingly, the ICER values estimated by NICE for the same 
subgroups showed a large variation (1X-3X fold difference) compared to ICER 
values estimated by manufacturers. Selected case studies highlighted that for 
several products, NICE is recommending treatments only for subgroups whose 
ICER values are within the cost effectiveness threshold. CONCLUSIONS: New 
products need robust broader population and subgroup analyses for insurance 
coverage.  
